Nov. 14 at 4:57 PM
$BMEA Biomea Fusion is not building just another metabolic-biotech: it’s advancing what they believe could become the next generation of oral therapies for two of medicine’s largest unmet needs — diabetes and obesity.
Its lead program is a potential first-in-class oral menin inhibitor designed to address the root cause of type 2 diabetes by targeting the loss of insulin-producing β-cells rather than just treating symptoms. The second asset is a next-gen oral GLP-1 receptor agonist designed for convenience and patient-friendly experience at scale.
Biomea is focused on transformational upsides, not incremental improvements.
Biomea’s assets could redefine the standard of care, open new market opportunities, and shift paradigms.
Watch the upcoming data, the regulatory milestones, and the management in cash-runway discipline. Join the conversation.
